BDX Stock Recent News

Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision tools Combination of leading monitoring and infusion platforms enables future innovation opportunities for closed–loop monitoring and treatment, integrating combined company data sets and interoperability capabilities Business renamed as BD Advanced Patient Monitoring, will be based in Irvine, Calif. and become part of BD Medical segment Katie Szyman will continue to lead BD Advanced Patient Monitoring as worldwide president FRANKLIN LAKES, N.J.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Emphasizes Value of Domestic Production of Critical Medical Devices FRANKLIN LAKES, N.J. , Aug. 22, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today celebrated the 75th anniversary of its manufacturing operations in Columbus, Neb.

FRANKLIN LAKES, N.J. , Aug. 12, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Michael Feld has been named executive vice president and president of the Life Sciences segment for BD, effective Aug. 20, 2024, and will serve as a member of the Executive Leadership Team.

Market volatility recently hit the 3rd highest levels ever recorded, and extreme fear grips Wall Street. The yen carry trade unwind is likely not over yet; US recession risks remain elevated, and the market decline might still have another 8%. Dividend aristocrats are down just 0.9% in this downturn, and many aristocrats are up modestly.

FRANKLIN LAKES, N.J. , Aug. 8, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 2024 Healthcare Conference on Wednesday, September 4, 2024 at 8:45 am Eastern Time.

Dividends have played a significant role in the total returns of equity investments. The practice of consistently increasing dividends can be seen in the S&P 500 Dividend Aristocrats.

Becton, Dickinson is overwhelmingly considered undervalued by Wall Street analysts, with an average price target of ~$280 and highs of $312-$330. This is supported by my extensive DCF and comps models. BDX benefits from innovative products, strategic partnerships, and ongoing trends. The company boasts high margins and a reliable, growing dividend. However, the price is already pretty close to its all-time high and most price targets, so significant further appreciation is unlikely, making BDX a very moderate "Buy".

BD's (BDX) overall topline benefits from revenue growth in all segments in the fiscal third quarter.

Becton, Dickinson and Company (NYSE:BDX ) Q3 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer & Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer & President Chris DelOrefice - Executive Vice President & Chief Financial Officer Mike Garrison - President of the Medical Segment Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America David Roman - Goldman Sachs Patrick Wood - Morgan Stanley Larry Biegelsen - Wells Fargo Rick Wise - Stifel Vijay Kumar - Evercore ISI Operator Hello and welcome to BD's Third Quarter Fiscal 2024 Earnings Conference Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website at investors.bd.com or by phone at 800-839-2385 for domestic calls and area code +1 402-220-7203 for international calls.